Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothe
Brief Summary: The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.